Clinicians 2018-05-13T16:25:45+00:00

Pharmacogenomic Testing

Our mission is to serve as a trusted partner to physicians, healthcare professionals and patients by providing quality testing services. Pharmacogenomics is being implemented into routine clinical practice as the medical and pharmaceutical industries move from a one-size-fits-all model to a personalized medicine approach. PGX testing can improve medication management by reducing trial and error prescribing, minimizing adverse drug reactions, improving medication compliance and quality of life, and managing health costs.

Test Panels

0%
80% of the population carries at least one mutation that affects drug metabolism.
Full list of medications reported

Includes 16 of the most important genes related to drug metabolism (ANKK1/DRD2, COMT, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F, HTR2A, HTR2C, MTHFR, OPRM1, SLCO1B1, VKORC1)

Includes 13 genes that metabolize the most commonly prescribed medications for both psychiatric and pain conditions (ANKK1/DRD2, COMT, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, HTR2A, HTR2C, MTHFR, OPRM1)

Includes 12 genes that metabolize the most commonly prescribed medications for psychiatric conditions, including SSRIs, tricyclic anti-depressants and anti-psychotics, ADHD and epilepsy (ANKK1/DRD2, COMT, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, HTR2A, HTR2C, MTHFR, OPRM1)

Include 9 genes that metabolize the most commonly prescribed medications for pain management (COMT, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, OPRM)

Includes 9 of the most important genes related to drugs prescribed for cardiology including genes for Plavix and Warfarin testing (CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F, MTHFR, SLCO1B1, VKORC1)

Testing Process

Our testing process is quick and easy. Once a licensed provider orders the test, the sample can be collected in the provider’s office. The Test Report is available within 7-10 days.

Highlights:

  • Non-invasive cheek swab that can be collected in the provider’s office
  • Easy access to reports through our secure online portal
  • Capable of integrating with electronic health record systems, in partnership with MedTek21

Billing Policy

Genemarkers is committed to providing patients with quality service, which includes ensuring a clear understanding of the billing process and access to a manageable payment arrangement. Most insurance plans, including Medicare and Medicaid, offer limited coverage of the test.

Self Pay

Genemarkers offers an affordable self-pay rate for each one of our panels for patients who are uninsured or those who have insurance and prefer not to bill their plan.

Commercially Insured

(including Medicare Advantage Plans)

Genemarkers will submit the insurance claim on behalf of patients.

After the insurance claim has been processed to the fullest extent, Genemarkers will bill patients for any out-of-pocket expenses. Genemarkers will bill patients for the amount determined by their insurance plan. This may be related to co-payments, co-insurance or deductibles.

Genemarkers has several options to help alleviate any financial burden due to out-of-pocket costs.

Traditional Medicare

PGX testing for most medical conditions is not currently covered by Medicare. Patients will need to sign an Advance Beneficiary Notice of Non-Coverage (ABN). If the test is not covered, the patient will be financially responsible. Patients can receive the self-pay rate if they elect not to bill Medicare and pay for the test out-of-pocket.

Medicaid

Genemarkers currently accepts Medicaid from several states. If the test is covered, there are no out-of-pocket costs.

Financial Assistance

Genemarkers has several financial support options to help alleviate any financial burden due to out-of-pocket costs, including:

prompt-pay discount

 zero interest payment plan

financial assistance plan for those who meet income-based guidelines

Insurance Coverage

Genemarkers encourages patients to confirm coverage with their insurance if they choose to bill their insurance. This guide will help with the information needed to reach out to insurers. Clinicians can provide the appropriate diagnosis codes (ICD10).

Insurance Coverage and Pre-Authorization Guide

Required Forms

In order to properly bill for the test, we need the following information.

Letter of Medical Necessity
Advance Beneficiary Notice of Noncoverage (ABN) (Medicare patients)
Copy of Insurance Card

PGX in the news

WSW: What Can Genetics Tells Up About Opioid Effectiveness And Addiction?

April 26, 2018, WMUK Radio – When some people take opioids it addresses their pain, and they have no trouble when it’s time to stop using them. But some people struggle to find the right pain relief, and others end up addicted. A new study being conducted in the Kalamazoo area is searching for the role genetics may play. […]

Study Pioneers Use Of Pharmacogenomic Data In Electronic Health Record

July 18, 2017, The Huffington Post – Nearly 1 out of every 3 American adults has high blood pressure. About 70 percent of them take medication for their condition, but only half have it under control. Why? The answer gets to the heart of precision medicine: Because each one of us has a unique genetic makeup, and we all respond differently to drugs. […]

Manchester joins partnership to offer pharmacogenomics training program

December 15, 2016, The Journal Gazette – Manchester University, RxGenomix and the American Pharmacists Association have teamed up to offer online training in pharmacogenomics (PGx). RxGenomix is working with the northeast Indiana university to help pharmacists and pharmacy students understand the fundamentals of PGx. […]

Following Newborn Pharmacogenomics Program, Inova Launches PGx Testing for Adults

November 17, 2016, Genome Web – After successfully rolling out a program that provided free pharmacogenomics profiling for newborns, the Inova Translational Medicine Institute is now offering PGx analysis for its adult patients. Currently, the PGx test, known as MediMap, is available through Inova’s concierge medicine program, but John Deeken, Inova’s chief operating officer, told GenomeWeb that the institute is working out details to offer it more broadly. […]

Getting Pharmacogenomics Into the Clinic

September 21, 2016, JAMA -What if there were a way to know if a depressed patient would respond to an antidepressant—before it was prescribed? Or to predict a bleeding event from an antiplatelet therapy? In recent years, advances in genetic testing have made such drug-response predictions possible for patients with certain gene variants. […]

Request a testing kit today
or reach out to learn more!

Request a Kit
Contact Us